Will a patient’s ABO blood type change from B‑positive to O‑positive after an allogeneic hematopoietic stem‑cell transplant, and how should transfusion support be managed?

Blood Group Conversion After Allogeneic HSCT: B+ to O+

Yes, a patient's blood type will convert from B-positive to O-positive after allogeneic hematopoietic stem cell transplantation, with the recipient's red blood cells gradually being replaced by donor-type cells over approximately 56-67 days, though serological complexities and persistent antigen expression can complicate blood typing and transfusion management 1.

Understanding the Conversion Process

The blood group conversion follows a predictable timeline based on the type of ABO incompatibility:

• Major ABO incompatibility (recipient B+, donor O+): RBC conversion averages 56.6 days 1
• Minor ABO incompatibility: RBC conversion averages 25.9 days 1
• Bidirectional incompatibility: RBC conversion takes longest at 67 days 1

The RBC chimeric growth ratio is approximately 1:9, gradually converting to the donor's blood group 1. White blood cell engraftment occurs much earlier, around 18.6 days on average 1.

Critical Serological Complexities

Persistent Antigen Expression

A major pitfall is that even with 100% donor chimerism, the recipient's original blood type antigens can persist on red blood cells 2, 3. This occurs because:

• Non-hematopoietic tissues (gut, vascular endothelium) continue producing the recipient's original ABO antigens
• These soluble antigens are secreted into plasma and adsorb onto donor-derived RBCs
• This phenomenon can persist for more than 1 year post-HSCT despite complete donor chimerism 3
• The persistence may increase during episodes of gastrointestinal GVHD 4

Isoagglutinin Dynamics

In your B+ to O+ scenario (major incompatibility):

• Recipient anti-A antibodies will disappear after conditioning (median 28 days) 1, 5
• The patient will eventually develop donor-type isoagglutinins (anti-A and anti-B, consistent with O blood type) 1
• Anti-A isoagglutinins persist longer than anti-B 5
• Persistent isoagglutinins correlate with increased early transfusion requirements 5

Transfusion Management Algorithm

Pre-Engraftment Period (Days 0-28)

Transfuse group O RBCs to avoid hemolysis from recipient's existing anti-A antibodies attacking donor O cells (not applicable in B→O scenario, but standard practice) 6, 7.

For your specific B+ to O+ case:

• Use O-positive RBCs during the early post-transplant period
• This avoids complications from residual recipient antibodies
• Platelets should be group O or AB to avoid passive transfer of anti-A/B antibodies 6

Transition Period (Days 28-67)

• Monitor isoagglutinin titers serially (IgM and IgG anti-A and anti-B) 5
• Continue O-positive RBCs until:
  • Recipient anti-A disappears (if present)
  • Donor RBC type clearly predominates
  • Complete donor chimerism confirmed

Post-Engraftment (After Day 67)

The patient should be transfused as blood type O-positive once full conversion is documented 1, 6.

However, perform detailed blood typing because:

• Weak expression of recipient B antigen may persist 2, 3
• This does NOT indicate graft failure if chimerism studies show 100% donor cells
• Use adsorption/elution studies if discrepancies exist between forward and reverse typing 4

Monitoring Requirements

Serial testing should include:

• ABO forward and reverse typing using both saline and gel methods 1
• Chimerism studies to confirm donor engraftment
• Isoagglutinin titers (IgM and IgG) 5
• Direct antiglobulin test (DAT) to detect antibody-coated RBCs 4

Common Pitfalls to Avoid

1. Do not interpret persistent B antigen as graft failure without confirming chimerism studies—this is likely soluble antigen adsorption 2, 3

2. Do not assume blood type conversion is complete at neutrophil engraftment—RBC conversion takes significantly longer (56+ days) 1

3. Watch for pure red cell aplasia in major ABO-incompatible transplants, particularly with anti-A antibodies (less relevant in B→O scenario but important principle) 8

4. Passenger lymphocyte syndrome is primarily a concern in minor ABO incompatibility (not applicable to B→O major incompatibility) 7

5. Increased transfusion burden is expected—persistent isoagglutinins correlate with higher PRBC and platelet requirements in the early post-transplant period 5